Abstract: | Memory consolidation is the process by which acquired information is converted to something concrete to be retrieved later. Here we examined a potential role for brain-derived neurotrophic factor (BDNF) in mediating the enhanced memory consolidation induced by the GABAA receptor antagonist, bicuculline methiodide. With the administration of an acquisition trial in naïve mice using a passive avoidance task, mature BDNF (mBDNF) levels were temporally changed in the hippocampal CA1 region, and the lowest levels were observed 9?h after the acquisition trial. In the passive avoidance task, bicuculline methiodide administration within 1?h of training but not after 3?h significantly increased latency time in the retention trial 24?h after the acquisition trial. Concomitantly, 1?h post-training administration of bicuculline methiodide, which enhanced memory consolidation, significantly increased mBDNF levels 9?h after training compared to those of the vehicle-treated control group. In addition, exogenous human recombinant BDNF (hrBDNF) administration 9?h after training into the hippocampal CA1 region facilitated memory consolidation confirming that the increase in mBDNF at around 9?h after training plays a key role in the enhancement of memory consolidation. Moreover, the increases in latency time and immediate early gene expressions by bicuculline methiodide or hrBDNF were significantly blocked by anisomycin, a protein synthesis inhibitor, K252a, a tyrosine receptor kinase (Trk) inhibitor, or anti-TrkB IgG. These findings suggest that the increase in the level of mBDNF and its function during a restricted time window after training are required for the enhancement of memory consolidation by GABAA receptor blockade. |